Course Summary
Brexpiprazole is an atypical, second-generation antipsychotic primarily used to treat adults with schizophrenia, a mental disorder characterized by hallucinations, delusions, and disorganized thinking. It is also approved for the adjunctive treatment of major depressive disorder (MDD) in adults, which means it can be used alongside an antidepressant to enhance its effects. Certain medical conditions, such as liver impairment or a history of seizures, may require dosage adjustments or monitoring. Brexpiprazole may also increase the risk of suicidal thoughts or behavior, particularly in younger individuals with major depressive disorder.
Course Format
Homestudy
Course Syllabus
- Introduction
- Pharmacological Profile, Dosing and Uses
- Major Depressive Disorder
- Schizophrenia
- Dementia due to Alzheimer’s Disease
- CYP2D6 Poor Metabolizers and CYP2D6 or CYP3A4 Inhibitors
- Dosing Adjustments: Geriatric, Hepatic and Renal
- Adverse Events, Contraindications and Warnings
- Special Patient Populations
- Suicidal Behavior and Ideation
- Precautions and Potential Clinical Complications
- Cardiovascular
- Central Nervous System
- Dyslipidemia
- Gastrointestinal
- Weight Gain
- Hyperglycemia
- Hematologic
- Neuroleptic Malignant Syndrome
- Temperature Regulation
- Seizure Disorder
- Hyperprolactinemia
- Drug Interactions and Overdose with Brexpiprazole Use
- Case Study: Brexpiprazole-Aripiprazole Combination Therapy
- Summary
Author
Richard Daniels, PharmD, BCPS
Richard “Cole” Daniels earned his Doctor of Pharmacy(PharmD) from the Skaggs School of Pharmacy at the University of Montana in 2018. Throughout pharmacy school he completed a 3-year internship at Community Medical Center in Missoula, Montana in which he gained valuable experience in an acute care setting. Cole currently serves as a psychiatric clinical staff pharmacist at the Montana State Hospital. He has over 11 years of pharmacy experience having worked in several settings including retail, acute care, and inpatient psychiatric care. Cole has a diverse set of interests. However, acute care medicine, infectious disease, pain management, and asthma/COPD are a primary focus of his at the Montana State Hospital. He obtained board certification as a certified pharmacotherapy specialist in the Spring of 2022.
